Drug has potential to prevent alcoholics from relapsing

Jul 30, 2008

An experimental drug that blocks the euphoric feelings associated with drinking may prevent alcoholics from relapsing. The finding, the result of a mouse study at Oregon Health & Science University, could lead to human clinical trials within the next year.

"We showed we could block behavior in mice that resembles this increased euphoria even after the animals had been given a lot of alcohol," said Tamara Phillips, Ph.D., professor and vice chair of the behavioral neuroscience department at OHSU and a research scientist at the Portland Veterans Affairs Medical Center. "That's what you want in a treatment, because we don't get to people until after they become addicted to alcohol."

Earlier research has shown that some people's brains become sensitized as a result of chronic exposure to alcohol. This change in the brain does not subside after people quit drinking. So when they begin consuming alcohol again, "they get a bigger jolt," Phillips said.

Alcohol consumption causes the body to release a substance known as "corticotrophin-releasing factor" or CRF. It activates receptors in the brain. Phillips and her team determined that a brain receptor called CRF1 appears to be involved in this heightened pleasure sensation. They compared the responses of normal mice and mice bred without the CRF1 receptor to chronic doses of alcohol. Mice without the CRF1 receptor did not experience the euphoric jolt the normal mice demonstrated.

The research team also took normal mice with the CRF1 receptor and exposed them to chronic doses of alcohol. Before testing for the euphoric response, the researchers gave the mice an experimental drug called CP 154,526 – developed by Pfizer – which prevents CRF from reaching the brain receptor. This group of mice also did not experience the heightened reaction.

Phillips' study recently was published in the Proceedings of the National Academy of the Sciences. The results may be particularly applicable to stress-induced relapse. That's because the CRF1 receptor also triggers the body's response to stress.

This could have implications for PTSD patients. "I think if you block this receptor, you might be able to decrease drinking in response to PTSD," Phillips said.

The next step is testing CP 154,526 to see if it is safe for use in humans. If it clears that hurdle, researchers will start human trials to determine if the drug can prevent alcoholic relapse.

Source: Oregon Health & Science University

Explore further: FDA: generic copaxone approved for multiple sclerosis

Related Stories

Modular Robotic Vehicle developed at Johnson Space Center

57 minutes ago

We all know Google's star act for driving's future with its self-driving car. What if NASA were to step up and give us its rendition of a self-driving vehicle? A new video reveals how NASA handles the role. NASA actually ...

Plight of imperiled Montana insect draws lawsuit

2 hours ago

Wildlife advocates asked a judge Wednesday to force federal officials to decide if a rare aquatic insect that's found only in Montana's Glacier National Park should be protected under the Endangered Species Act.

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.